{
  "id": 208639,
  "title": "US regulators approve Moderna flu vaccine",
  "url": "https://urgent.news/2026/08/06/us-regulators-approve-moderna-flu-vaccine",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-06T07:08:41.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-08-moderna-flu-vaccine.html"
  },
  "original_language": "en",
  "account": "The U.S. Food and Drug Administration (FDA) has approved Moderna's new influenza vaccine, mFLUSIVA, for use in all adults aged 50 and older, according to the company's release. This mRNA-based vaccine, which utilizes a new technology, was initially rejected by FDA regulators in February due to concerns about the clinical trials. However, after a \"constructive\" meeting, the FDA reversed its decision. mFLUSIVA is expected to be available in the United States for the 2026-2027 respiratory virus season. The vaccine's approval comes as global health authorities continue to support mRNA technology, which was instrumental in the rapid development of COVID-19 vaccines.",
  "summary": "The U.S. Food and Drug Administration (FDA) has approved Moderna's first mRNA-based influenza vaccine, mFLUSIVA, for use in all adults aged 50 and older. The vaccine manufacturer announced this news on Wednesday, nearly six months after the regulator briefly rejected the application for review. Moderna expects to make the vaccine available for eligible populations in the U.S. for the 2026-2027 respiratory virus season.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}